One major and often overlooked factor contributing to this imbalance is the way health outcomes are measured in clinical ...

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...

More details have emerged of a UK plan for new medicines to get simultaneous decisions from the MHRA and NICE on their use by the NHS.

Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.

Three key lessons the past five years of challenges and experience have taught us that we can use to move the biosimilars market forward.

At ASCO 2025 in Chicago, pharmaphorum web editor Nicole Raleigh spoke with Dr Jason Williams, director of interventional ...

Uniting 100+ precision medicine leaders from biopharma, diagnostic development, regulation, and healthcare institutes, the ...

We assume that what worked in the 1950s still works now. We assume that more budget is the only answer. Yet, AI can help in transformative ways if adopted at scale. If AI were scaled across the NHS to ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The smartphone-based CT-155 app, co-developed by Click Therapeutics and Boehringer Ingelheim, was able to help users achieve ...

Targovax interviewed by pharmaphorum said the market for oncolytic viruses is set to get increasingly crowded in the future as pharma tries to use the approach to improve efficacy of checkpoint ...